Jonah Feldman is an assistant editor for Targeted Oncology and Peers and Perspectives in Oncology. He covers a range of topics within medicine and healthcare, with a focus on oncology, immunotherapy, hematology, and patient care, while also exploring themes related to public health and alternative medicine. Jonah's work has been featured in notable publications such as Urology Times, Oncology Nursing News, OncLive, and CURE Media Group.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jonah Feldman's articles primarily focus on medical research, particularly in the field of oncology and hematology. His coverage heavily relies on data citation, indicating a preference for evidence-based information.
Given his emphasis on citing data, Jonah may be interested in pitches offering access to new clinical trial results or academic studies related to oncology and hematology. Additionally, he seems receptive to expert commentary from professionals involved in these fields who can provide nuanced insights into emerging treatments or therapeutic approaches.
It is important for those reaching out to Jonah Feldman with relevant pitches to ensure that the sources provided are credible experts within the healthcare and pharmaceutical industry and possess a deep understanding of the specific topics covered such as multiple myeloma, bispecific combination therapy, treatment response etc.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jonah Feldman
A 6-center Chinese phase 3 trial showed similar day-100 grade 2–4 aGVHD and 1-year GRFS across ATG, PTCy, and low-dose ATG/PTCy prophylaxis in haplo-PBSCT. Comparable 2-year overall survival, disease-free survival, relapse, and nonrelapse mortality were observed; age ≥55 years independently predicted inferior survival endpoints and higher nonrelapse mortality.
By: Jonah Feldman
FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in progressive mCRPC after one ARPI and ⁶⁸Ga-PSMA-11 PET. Lead-in cohorts combining TLX591-Tx with enzalutamide, abiraterone, or docetaxel showed no emergent unexpected toxicities; nonhematologic AEs were mostly grade 1–2 fatigue, nausea, and xerostomia.
By: Peter Voorhees, Jonah Feldman
In an interview, Peter Voorhees, MD, discusses why talquetamab is typically sequenced after BCMA-targeting agents and the unique situations where it might be used first.
By: Jonah Feldman
Peter Voorhees, MD, discusses the cost-benefit question of adding pomalidomide to daratumumab and talquetamab in early relapsed multiple myeloma.
Adam Cuker, MD, MS, discusses how the goals of treatment for immune thrombocytopenia have developed beyond managing platelet count.
By: Melody Chang, Jonah Feldman
In an interview, Melody Chang, RPh, MBA, BCOP, explains the work that went into ensuring access to bispecific antibodies across a network of community oncology practices.
By: Jonah Feldman, Sabrina Serani
PTEN IHC CDx is FDA-approved to detect PTEN protein loss and determine eligibility for capivasertib in PTEN-deficient metastatic prostate cancer. CAPItello-281 enrolled newly diagnosed PTEN-deficient mAPMN/S patients and showed rPFS improvement with capivasertib plus abiraterone/prednisone and ADT versus control.
By: Jonah Feldman
SER-155 led to short-term improvement in diarrhea management in patients receiving immune checkpoint inhibitors.
By: Jonah Feldman
Doris K. Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
By: Jonah Feldman
During a live event, Prerna Mewawalla, MD, discussed the choice between bispecific antibody therapy and CAR T-cell therapy in myeloma as both therapies have been introduced earlier in sequence.
